ClinicalTrials.gg
Active, not recruitingNCT05334732SISUpdated Aug 26, 2026

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

An interventional study of SIS TALK Back Intervention in Breast Cancer, sponsored by Virginia Commonwealth University. Active, not recruiting at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Virginia Commonwealth University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2021, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Breast Neoplasms by Virginia Commonwealth University — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Virginia Commonwealth University.

Enrollment
3rd of 23
225 · median 46
Started
2021
with 1 other
No phase
9 of 26
1 open now
Registered
20th of 26
by date

Among the 26 studies in Breast Neoplasms by Virginia Commonwealth University, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2021, is one of 9 with no phase, and was the 20th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 26 studies in Breast Neoplasms by Virginia Commonwealth University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by Virginia Commonwealth University, or all of them as a file.
02

Study summary

The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.

Read the detailed description

Black women continue to experience worse breast cancer outcomes, which may be due to inadequate adherence to systemic therapies that can be improved via patient-centered communication. We developed and piloted the Sisters Informing SistersSM (SIS) intervention (survivor-led skill-building sessions and culturally tailored materials to activate Black breast cancer survivors in their medical encounters) and obtained promising findings. This project will compare in a two-arm RCT the impact of SIS vs. enhanced usual care (treatment recommendation summary form) on patient-centered communication and systemic treatment adherence; SIS tools may be integrated within existing clinical and support services.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Black Women
  • Breast Cancer Survivor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Self-identify as Black
  • Newly diagnosed (\~4 weeks post-definitive surgery and prior to initiation of chemotherapy or endocrine therapy) patients (stage I-III)
  • Eligible for chemotherapy or endocrine therapy according to NCCN guidelines, but have not initiated systemic therapy
  • Ability to read and speak English
  • Ability to provide meaningful consent as determined by trained study personnel and/or a member of the patient's care team
  • No prior cancer treatment (other than skin cancer) in the two years preceding enrollment
  • Physicians Must be a license doctor of study patient(s)
  • Ability to speak English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Sisters Informing Sisters Sessions

    The intervention is peer-based and in concert with our theoretical model, builds upon positive role-modeling of the survivor coach to the patient, addresses behavioral expectations/capacities, and uses Motivational Interviewing (MI) techniques. The intervention includes a culturally relevant coach's manual and a patient workbook that will be used to facilitate the coaching sessions.

    Behavioral: SIS TALK Back Intervention

  • No intervention
    Enhanced Usual Care

    Women in the EUC arm will receive usual care that includes standardized information in the public domain (NCI treatment information booklet). This booklet was chosen to provide women with national-level recommendations regarding treatment recommendations.

Interventions

  • BehavioralSIS TALK Back Intervention

    The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.

06

What researchers measure

Primary outcomes

  1. Assessing Study Adherence Behaviors- Initiation

    Initiation will be measured for all therapies based on the number of participants starting at least one cycle of prescribed therapy

    Time frame: 36 Months

  2. Assessing Study Adherence Behaviors- Delay of Adjuvant or Endocrine Therapy.

    Initiation Delay of therapy will be measured by the number of participant's days from definitive surgery date to the date of her first cycle of adjuvant systemic therapy. Classifications of delay are dichotomized according to published reports (\<60 days primary measure).

    Time frame: 36 Months

  3. Assessing Study Adherence Behaviors- Overall Chemotherapy Adherence

    Overall chemotherapy adherence will be measured by the number of participants that complete chemotherapy. Chemotherapy adherence will be measured as having at least 80% or more of the recommended doses. Adherence will be calculated based on the planned and expected number of cycles divided by the number received (i.e., 6 chemotherapy cycles received/8 expected = 75% adherent).

    Time frame: 36 Months

Secondary outcomes

  1. Assess Perceived Involvement in Care: PCC Outcomes - Level of Engagement in Decision Making

    The number of participants level of engagement in decision-making will be assessed by utilizing The Perceived Involvement in Care (PCC) 13-Item scale. PCC will be assessed via direct observation of medical encounters through a quantitative analysis of audiotaped visits.

    Time frame: 36 Months

  2. Assess Perceived Involvement in Care: PCC Outcomes - Perceptions of Doctor Behaviors by determining a more patient-centered encounter vs a more biomedically focused encounter.

    The number of participants level of engagement in perceptions of doctor behaviors will be assessed by utilizing The Perceived Involvement in Care (PCC) 13-Item scale. PCC will be assessed via direct observation of medical encounters through a quantitative analysis of audiotaped visits. A value \>1 indicates a more patient-centered encounter, whereas a value \<1 indicates a more biomedically focused encounter.

    Time frame: 36 Months

  3. Assess Perceived Involvement in Care: PCC Outcomes - Perceptions of Patient Behaviors by determining Perceptions of Doctor Behaviors by determining a more patient-centered encounter vs a more biomedically focused encounter

    The number of participants level of engagement in perceptions of patient behaviors will be assessed by utilizing The Perceived Involvement in Care (PCC) 13-Item scale. PCC will be assessed via direct observation of medical encounters through a quantitative analysis of audiotaped visits. A value \>1 indicates a more patient-centered encounter, whereas a value \<1 indicates a more biomedically focused encounter.

    Time frame: 36 Months

  4. Determine Process and Implementation Outcomes

    Assess the number of participants who Consent to Participate in the trial

    Time frame: 36 Months

  5. Determine Process and Implementation Outcomes

    Assess the number of participants that participate in the trial after they sign consent

    Time frame: 36 Months

  6. Determine Process and Implementation Outcomes

    Assess the Cost of the trial per arm. Personnel time costs will be obtained by multiplying the staff time. costs by hourly average wage and fringe benefit rates. The staff time will include the training to identify at-risk women and the time spent administering/reviewing study materials including the treatment summary request form

    Time frame: 36 Months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Feb 2027, 71 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 71 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 19, 2022
StartActual
Mar 1, 2021
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05334732
Responsible party
Sponsor
First posted
Apr 19, 2022
Start date
Mar 1, 2021
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Vanessa B Sheppard, Ph.D
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion